P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH. (March 2015) - Jackisch, C.; Hegg, R.; Stroyakovskiy, D.; Ahn, J.; Melichar, B.; Chen, S.C.; Crepelle-Flechais, A.; Heinzmann, D.; Shing, M.; Pivot, X.